Latest news

Commercial

Anthropic Confirms Bay Area Wet Lab as It Expands Life Sciences Efforts

Anthropic has established a wet laboratory in the San Francisco Bay Area as part of its growing life sciences...
Clinical

Bristol Myers Squibb Ends Development of Orum’s ORM-6151 After Phase 1 Review

Bristol Myers Squibb has discontinued development of ORM-6151, a degrader-antibody conjugate (DAC) acquired from South Korean biotechnology company Orum...
Clinical

Phase 3 depression trials halted by Xenon following psychosis episodes

Trial Enrolment Paused Over Neuropsychiatric Adverse Events Xenon Pharmaceuticals has stopped enrolling patients in its phase 3 depression trials after...
Commercial

Telix to Acquire ITM in $1.65 Billion Deal Centered on ITM-11 and Radiopharmaceutical Expansion

Australia-based Telix Pharmaceuticals has agreed to acquire Germany’s ITM Isotope Technologies Munich in a transaction valued at $1.65 billion...
Clinical

Despite failing the phase 2 ALS investigation, Axoltis will continue using the synthetic peptide

Phase 2 Trial Overview and Primary Endpoint Results French biotech...
Regulatory

BMS and Ono Challenge Amgen as Opdivo Biosimilar Nears FDA Review

Bristol Myers Squibb and Ono Pharmaceutical have filed a...
Manufacturing

Reckitt Plans $600 Million U.S. Expansion Across Manufacturing and R&D

Reckitt is investing up to $600 million over several years to expand and modernize its U.S. operations, with the...
Insights

Top 10 Trends Driving Adaptive Clinical Trials

Executive Summary Clinical trials are becoming increasingly complex as pharmaceutical companies evaluate more targeted therapies, recruit diverse patient populations, and...
Clinical

Electra Plans to Advance Ipsoprubart Through Phase 2/3 sHLH Study

Electra Therapeutics plans to use proceeds from a proposed initial public offering to advance development of its lead drug...
Regulatory

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy

Scholar Rock has received U.S. Food and Drug Administration...
Clinical

J&J’s Depression Drug Fails Another Phase 2 Test

A phase 2 study of Johnson & Johnson’s JNJ-5120...
Insights

Edge AI in Healthcare

Executive Summary Artificial intelligence is becoming increasingly embedded in healthcare, but many AI applications still depend on centralized cloud infrastructure...
Insights

Building a Future-Ready Life Sciences Organization

Executive Summary The life sciences industry is entering a period of structural change. Scientific innovation is accelerating, healthcare systems are becoming...
Regulatory

FDA Extends Review of Exelixis’ Zanzalintinib-Tecentriq Combination for Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has extended its review of Exelixis’ application for zanzalintinib in combination with...
Regulatory

Beacon Gets Important Trial Win For Vision Loss Treatment; FDA Nod Likely

Beacon Therapeutics has reported a pivotal clinical success for...
Editorial Team -
Commercial

Merck broadens the supply of COVID 19 pills in China

Merck has collaborated with Sinopharm to exclusively distribute and...
Commercial

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit...

Popular

Most popular life news you must read today

View all articles

Commercial

Information Technology

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Suki announced Tuesday the release of Suki Dictation, an artificial intelligence-powered dictation solution designed...
Editorial Team -

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

Healthcare-related infections remain a persistent challenge for hospitals, affecting roughly one in every 40...
Editorial Team -

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

The U.S. Food and Drug Administration (FDA) granted Johnson & Johnson De Novo clearance...
Editorial Team -

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Alnylam has entered into a partnership with the scientist instrumental in developing the technology...
Editorial Team -

Regulatory

Regulatory

Beacon Gets Important Trial Win For Vision Loss Treatment; FDA Nod Likely

Beacon Therapeutics has reported a pivotal clinical success for...
Editorial Team -
Clinical

Bristol Myers Squibb Ends Development of Orum’s ORM-6151 After Phase 1 Review

Bristol Myers Squibb has discontinued development of ORM-6151, a...
Clinical

Phase 3 depression trials halted by Xenon following psychosis episodes

Trial Enrolment Paused Over Neuropsychiatric Adverse Events Xenon Pharmaceuticals has...
Commercial

Telix to Acquire ITM in $1.65 Billion Deal Centered on ITM-11 and Radiopharmaceutical Expansion

Australia-based Telix Pharmaceuticals has agreed to acquire Germany’s ITM...
Regulatory

Beacon Gets Important Trial Win For Vision Loss Treatment; FDA Nod Likely

Beacon Therapeutics has reported a pivotal clinical success for...

Research & Development

Market Access

Manufacturing

Takeda Plans 4,500 Job Cuts as CEO Transition and Three Drug Launches Approach

Takeda has outlined plans to reduce around 4,500 roles...
Manufacturing

Daiichi Revises ADC Supply Plans After Changes in Cancer Drug Demand Forecasts

Daiichi Sankyo said changes in projected demand for several...

Manufacturing & RegulatoryPOPULAR
Find Your Perfect Music Festival

Manufacturing

ArsenalBio Lays Off 99 Employees and Shifts Focus to In Vivo CAR-T Programs

Arsenal Biosciences (ArsenalBio) is reducing its workforce by 99...
Editorial Team -
Clinical

Phase 3 depression trials halted by Xenon following psychosis episodes

Trial Enrolment Paused Over Neuropsychiatric Adverse Events Xenon Pharmaceuticals has...
Editorial Team -